Merck Sharp & Dohme fails to secure new nasal spray trial
The US Court of Appeals for the Federal Circuit denied Merck Sharp & Dohme’s (MSD) request for a new trial to determine whether Amneal infringed a patent related to a nasal spray on Friday, February 9.
If you don't have a login or your access has expired, you will need to purchase a subscription to gain access to this article, including all our online content.
For more information on individual annual subscriptions for full paid access and corporate subscription options please contact us.
To request a FREE 2-week trial subscription, please signup.
NOTE - this can take up to 48hrs to be approved.
For multi-user price options, or to check if your company has an existing subscription that we can add you to for FREE, please email Adrian Tapping at atapping@newtonmedia.co.uk
12 October 2021 Bayer Healthcare and drug importer Meda Pharmaceuticals have sued generic manufacturer Apotex, alleging that its planned generic nasal spray infringes on Bayer’s Astepro patents.
12 October 2021 Bayer Healthcare and drug importer Meda Pharmaceuticals have sued generic manufacturer Apotex, alleging that its planned generic nasal spray infringes on Bayer’s Astepro patents.
12 October 2021 Bayer Healthcare and drug importer Meda Pharmaceuticals have sued generic manufacturer Apotex, alleging that its planned generic nasal spray infringes on Bayer’s Astepro patents.